17-44385705-GGGGGCGCAGGCCT-G

Variant summary

Our verdict is Pathogenic. Variant got 15 ACMG points: 15P and 0B. PM2_SupportingPS3PP4_StrongPM3PVS1_Strong

This summary comes from the ClinGen Evidence Repository: The c.409-2_419del variant was first reported in the Palestinian population by PMID:2014236; haplotype analysis in PMID:16359514 is consistent with a founder effect. This variant has also been described as c.409-3_418del and HGVS nomenclature is c.409-4_417del. The deletion causes use of a cryptic splice site at position c.425_426 (confirmed in patient mRNA in PMID:2014236). As such there is an in-frame deletion of 18bp encompassing 6 amino acids (Ala137 through Gln142) in the critical ligand binding beta-propeller domain. This variant is absent from all population databases, including gnomAD. The variant has been identified homozygous in at least 8 patients (PMIDs: 2014236, 16359514). with a phenotype highly specific to GT. Transfection in BHK cells resulted in lack of surface expression of αIIbβ3 (PMID:16359514). In summary this variant is classified as Pathogenic for GT. GT-specific criteria applied: PVS1_strong, PS3, PM2_supporting, PM3, PP4_strong. LINK:https://erepo.genome.network/evrepo/ui/classification/CA10575471/MONDO:0010119/011

Frequency

Genomes: not found (cov: 32)

Consequence

ITGA2B
NM_000419.5 splice_acceptor, coding_sequence

Scores

Not classified

Clinical Significance

Pathogenic reviewed by expert panel P:2

Conservation

PhyloP100: 8.06
Variant links:
Genes affected
ITGA2B (HGNC:6138): (integrin subunit alpha 2b) This gene encodes a member of the integrin alpha chain family of proteins. The encoded preproprotein is proteolytically processed to generate light and heavy chains that associate through disulfide linkages to form a subunit of the alpha-IIb/beta-3 integrin cell adhesion receptor. This receptor plays a crucial role in the blood coagulation system, by mediating platelet aggregation. Mutations in this gene are associated with platelet-type bleeding disorders, which are characterized by a failure of platelet aggregation, including Glanzmann thrombasthenia. [provided by RefSeq, Jan 2016]

Genome browser will be placed here

ACMG classification

Classification made for transcript

Verdict is Pathogenic. Variant got 15 ACMG points.

PVS1
For more information check the summary or visit ClinGen Evidence Repository.
PS3
For more information check the summary or visit ClinGen Evidence Repository.
PM2
For more information check the summary or visit ClinGen Evidence Repository.
PM3
For more information check the summary or visit ClinGen Evidence Repository.
PP4
For more information check the summary or visit ClinGen Evidence Repository.

Transcripts

RefSeq

Gene Transcript HGVSc HGVSp Effect #exon/exons MANE Protein UniProt
ITGA2BNM_000419.5 linkuse as main transcriptc.409-2_419del splice_acceptor_variant, coding_sequence_variant 4/30 ENST00000262407.6 NP_000410.2
ITGA2BXM_011524749.2 linkuse as main transcriptc.562-2_572del splice_acceptor_variant, coding_sequence_variant 4/29 XP_011523051.2
ITGA2BXM_011524750.2 linkuse as main transcriptc.562-2_572del splice_acceptor_variant, coding_sequence_variant 4/29 XP_011523052.2

Ensembl

Gene Transcript HGVSc HGVSp Effect #exon/exons TSL MANE Protein Appris UniProt
ITGA2BENST00000262407.6 linkuse as main transcriptc.409-2_419del splice_acceptor_variant, coding_sequence_variant 4/301 NM_000419.5 ENSP00000262407 P1P08514-1
ITGA2BENST00000592944.1 linkuse as main transcriptn.92_104del non_coding_transcript_exon_variant 1/65

Frequencies

GnomAD3 genomes
Cov.:
32
We have no GnomAD4 exomes data on this position. Probably position not covered by the project.
GnomAD4 genome
Cov.:
32

ClinVar

Significance: Pathogenic
Submissions summary: Pathogenic:2
Revision: reviewed by expert panel
LINK: link

Submissions by phenotype

Glanzmann thrombasthenia Pathogenic:1
Pathogenic, reviewed by expert panelcurationClinGen Platelet Disorders Variant Curation Expert Panel, ClinGenMay 07, 2021The c.409-2_419del variant was first reported in the Palestinian population by PMID: 2014236; haplotype analysis in PMID: 16359514 is consistent with a founder effect. This variant has also been described as c.409-3_418del and HGVS nomenclature is c.409-4_417del. The deletion causes use of a cryptic splice site at position c.425_426 (confirmed in patient mRNA in PMID: 2014236). As such there is an in-frame deletion of 18bp encompassing 6 amino acids (Ala137 through Gln142) in the critical ligand binding beta-propeller domain. This variant is absent from all population databases, including gnomAD. The variant has been identified homozygous in at least 8 patients (PMIDs: 2014236, 16359514). with a phenotype highly specific to GT. Transfection in BHK cells resulted in lack of surface expression of αIIbβ3 (PMID: 16359514). In summary this variant is classified as Pathogenic for GT. GT-specific criteria applied: PVS1_strong, PS3, PM2_supporting, PM3, PP4_strong. -
Glanzmann thrombasthenia 1 Pathogenic:1
Pathogenic, no assertion criteria providedliterature onlyOMIMJul 12, 1991- -

Computational scores

Source: dbNSFP v4.3

Name
Calibrated prediction
Score
Prediction

Splicing

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

LitVar

Below is the list of publications found by LitVar. It may be empty.

Other links and lift over

dbSNP: rs879255508; hg19: chr17-42463073; API